Meet the editors | Cancer research
Discuss your cancer research with one of our editors.
Discuss your cancer research with one of our editors.
At the 2024 UCSF-UCLA PSMA Conference, Matthew Rettig discusses the critical advancements and challenges in treating metastatic castration-resistant prostate cancer (mCRPC), highlighting the shift towards…
APCCC 2024, metastatic castration resistant prostate cancer (mCRPC), PARP Inhibitions, DNA Repair Gene Alterations, ribonucleotide excision genes, TOPARP trial, olaparib, talazoparib, PROfound trial, PROpel trial.
APCCC 2024, prostate cancer, Metastatic Castration Resistant Prostate Cancer (mCRPC), PARP Inhibitors, BRCA-deficient metastatic prostate cancer, TOPARP-B trial, olaparib, olaparib monotherapy, PROFOUND trial, androgen receptor…
upper tract urothelial carcinoma (UTUC), circulating tumor DNA (ctDNA), circulating tumor DNA in upper tract urothelial carcinoma, Non-organ-confined Upper Tract Urothelial Carcinoma, Muscle-invasive Upper Tract…
APCCC 2024, Advanced Prostate Cancer, Cardiovascular Complications in Advanced Prostate Cancer, androgen deprivation therapy (ADT), Androgen deprivation therapy-related cardiovascular toxicities, RADICAL-PC trial.
The Milestones in Action library aid parents and providers with examples of important developmental milestones for children ages 2 months to 5 years.
Histone deacetylases (HDACs) are important chromatin regulators essential for plant tolerance to adverse environments. In addition to histone deacetylation and epigenetic regulation, HDACs deacetylate non-histone…
Sam Chang engages with Jennifer Linehan to discuss topical chemotherapy for upper tract urothelial carcinoma, particularly utilizing UGN-101 (Jelmyto). Dr. Linehan shares her invaluable insights…
APCCC 2024, PSMA Radioligand Therapy, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), PSMA-617, PSMA-1&T, PSMA-1007 rhPSMA-7, 68Ga PSMA-11, VISION trial, TheraP trial, PSMAfore trial,…
APCCC 2024, prostate cancer, metastatic castrate-sensitive prostate cancer (mCSPC), non-DNA Damage Response (DDR) genomic alteration, Non-DDR Genomic Alterations, Advanced Prostate Cancer, SWOG2312 trial, RET fusions,…